Sage Journals: Discover world-class research

Abstract

Background:

Recent progress in multiple sclerosis (MS) management has contributed to a greater life expectancy in persons with MS. Ageing with MS comes with unique challenges and bears the potential to greatly affect quality of life and socioeconomic burden.

Objectives:

To compare frailty in ageing persons with multiple sclerosis (pwMS) and controls; to correlate frailty with MS clinical characteristics.

Methods:

PwMS and controls over 50 years old were recruited in a cross-sectional study. Two validated frailty measures were assessed: the frailty index and the Fried’s phenotype. Several multiple linear regressions accounting for demographic and clinical characteristics were performed.

Results:

Eighty pwMS (57 females, mean age 58.5 ± 6 years old) and 37 controls (24 females, mean age 61 ± 6.5 years old) were recruited. Multivariable analysis identified significantly higher frailty index in pwMS (0.21 ± 0.12 vs 0.11 ± 0.08, p < 0.0001). Similarly, according to Fried’s phenotype, a significantly higher percentage of pwMS were frail compared to controls (28% vs 8%). In pwMS, frailty index was independently associated with expanded disability status scale (EDSS), comorbidities, education level and disease duration.

Conclusion:

Our results suggest that frailty can be routinely assessed in pwMS. Increased frailty in MS patients suggests that, along with MS therapeutics, a tailored multidisciplinary approach of ageing pwMS is needed.

Keywords

Multiple sclerosis ageing frailty Fried’s phenotype quality of life comorbidities

Get full access to this article

View all access options for this article.

References

Reich

Lucchinetti

Calabresi

PA.

Multiple sclerosis. N Engl J Med 2018; 378(2): 169–180.

Scalfari

Neuhaus

Daumer

, et al. Age and disability accumulation in multiple sclerosis. Neurology 2011; 77(13): 1246–1252.

Kappos

Kuhle

Multanen

, et al. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15. J Neurol Neurosurg Psychiatry 2015; 86(11): 1202–1207.

Brownlee

Altmann

Prados

, et al. Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain J Neurol 2019; 142(8): 2276–2287.

Marrie

Elliott

Marriott

, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology 2015; 85(3): 240–247.

Lunde

HMB

Assmus

Myhr

K-M

, et al. Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. J Neurol Neurosurg Psychiatry 2017; 88(8): 621–625.

Comber

Quinn

McGuigan

, et al. Medication usage and falls in people with multiple sclerosis. Mult Scler 2018; 24(7): 995–998.

Sanai

Saini

Benedict

, et al. Aging and multiple sclerosis. Mult Scler J 2016; 22(6): 717–725.

Kingwell

van der Kop

Zhao

, et al. Relative mortality and survival in multiple sclerosis: Findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 2012; 83(1): 61–66.

10.

Clegg

Young

Iliffe

, et al. Frailty in elderly people. Lancet 2013; 381(9868): 752–762.

11.

Collard

Boter

Schoevers

, et al. Prevalence of frailty in community-dwelling older persons: A systematic review. J Am Geriatr Soc 2012; 60(8): 1487–1492.

12.

Fried

Tangen

Walston

, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146–M156.

13.

Song

Mitnitski

Rockwood

Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc 2010; 58(4): 681–687.

14.

Guaraldi

Brothers

Zona

, et al. A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS 2015; 29(13): 1633–1641.

15.

Alonso Salinas

Sanmartin

Pascual Izco

, et al. Frailty is an independent prognostic marker in elderly patients with myocardial infarction. Clin Cardiol 2017; 40: 925–931.

16.

Lytwyn

Stammers

Kehler

, et al. The impact of frailty on functional survival in patients 1 year after cardiac surgery. J Thorac Cardiovasc Surg 2017; 154: 1990–1999, https://linkinghub.elsevier.com/retrieve/pii/S0022522317313594 (accessed 16 September 2019).

17.

Guler

Kwan

Winstone

, et al. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease. Respir Med 2017; 129: 1–7.

18.

Martin

Raffel

Nicholas

Progressive dwindling in multiple sclerosis: An opportunity to improve care. PLoS ONE 2016; 11(7): e0159210.

19.

Kingwell

Leray

Zhu

, et al. Multiple sclerosis: Effect of beta interferon treatment on survival. Brain J Neurol 2019; 142(5): 1324–1333.

20.

Lorscheider

Buzzard

Jokubaitis

, et al. Defining secondary progressive multiple sclerosis. Brain 2016; 139(9): 2395–2405.

21.

Horton

Rudick

Hara-Cleaver

, et al. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology 2010; 35(2): 83–90.

22.

Leplege

Ecosse

Verdier

, et al. The French SF-36 health survey: Translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998; 51(11): 1013–1023.

23.

Kobelt

Thompson

Berg

, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J 2017; 23(8): 1123–1136.

24.

Mitnitski

Mogilner

Rockwood

Accumulation of deficits as a proxy measure of aging. Sci World J 2001; 1: 323–336.

25.

Bigard

Duforez

Portero

, et al. Détermination de l’activité physique par questionnaire: Validation du questionnaire autoadministrable de Baecke. Sci Sports 1992; 7(4): 215–221.

26.

Searle

Mitnitski

Gahbauer

, et al. A standard procedure for creating a frailty index. BMC Geriatr 2008; 8(1): 24, http://bmcgeriatr.biomedcentral.com/articles/10.1186/1471-2318-8-24 (accessed 16 September 2019).

27.

Goodin

DS.

The epidemiology of multiple sclerosis: Insights to disease pathogenesis. In: Goodin

(ed.) Handbook of clinical neurology, vol. 122. New York: Elsevier, 2014, pp. 231–266, https://linkinghub.elsevier.com/retrieve/pii/B9780444520012000108 (accessed 16 September 2019).

28.

Tutuncu

Tang

Zeid

, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 2013; 19(2): 188–198.

29.

Buhse

Banker

Clement

LM.

Factors associated with health-related quality of life among older people with multiple sclerosis. Int J MS Care 2014; 16(1): 10–19.

30.

Zhang

Tremlett

Zhu

, et al. Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology 2018; 90(5): e419–e427.

31.

McKay

Marrie

Fisk

, et al. Comorbidities are associated with altered health services use in multiple sclerosis: A prospective cohort study. Neuroepidemiology 2018; 51(1–2): 1–10.

32.

Balto

Pilutti

Motl

RW.

Loneliness in multiple sclerosis: Possible antecedents and correlates. Rehabil Nurs. Epub ahead of print 3 January 2018. DOI: 10.1097/RNJ.0000000000000128.

33.

Pearson

Alla

Clarke

, et al. Multiple Sclerosis impact on employment and income in New Zealand. Acta Neurol Scand 2017; 136(3): 223–232.

34.

Grebenciucova

Pruitt

Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep 2017; 17(11): 88.

35.

Satake

Senda

Hong

Y-J

, et al. Validity of the Kihon checklist for assessing frailty status. Geriatr Gerontol Int 2016; 16(6): 709–715.

36.

Thabane

Ioannidis

, et al. Comparison between frailty index of deficit accumulation and phenotypic model to predict risk of falls: Data from the global longitudinal study of osteoporosis in women (GLOW) Hamilton cohort. PLoS ONE 2015; 10(3): e0120144.

37.

Yeoh

H-L

Cheng

Palmer

, et al. Frailty in men living with HIV: A cross-sectional comparison of three frailty instruments. Antivir Ther 2017; 23(2): 117–127.

38.

Tan

Hew

Lim

S-Y

, et al. Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson’s disease. Parkinsonism Relat Disord 2018; 56: 58–64.

39.

Hanlon

Nicholl

Jani

, et al. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: A prospective analysis of 493 737 UK Biobank participants. Lancet Public Health 2018; 3(7): e323–e332.

40.

Tallantyre

Major

Atherton

, et al. How common is truly benign MS in a UK population? J Neurol Neurosurg Psychiatry 2019; 905: 522–528.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

Frailty in ageing persons with multiple sclerosis

Abstract

Background:

Objectives:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material